Joseph LaRosa - Regeneron Pharmaceuticals Senior Vice President General Counsel, Secretary

REGN -- USA Stock  

USD 295.87  9.72  3.40%

  President
Mr. Joseph J. LaRosa is an Senior Vice President, General Counsel, Secretary of the Company. Mr. LaRosa was Senior Vice President, General Counsel, and Secretary at Nycomed US Inc. Mr. LaRosas prior experience includes working in a number of senior legal positions at ScheringPlough Corporationrationration from 1993 to 2009, where he was a corporate officer and served most recently as Vice President, Legal Affairs, and a member of the Operations Management Team
Age: 59  President Since 2019      
914-847-7000  http://www.regeneron.com
LaRosa received his J.D. from New York University School of Law.

Management Efficiency

The company has return on total asset (ROA) of 11.57 % which means that it generated profit of $11.57 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 24.43 % meaning that it created $24.43 on every $100 dollars invested by stockholders.
The company currently holds 711.3M in liabilities with Debt to Equity (D/E) ratio of 7.2 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Regeneron Pharmaceuticals has Current Ratio of 3.8 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives

PRESIDENT Since

Samiran DasDr Reddys Laboratories Ltd
2016
Amit SachdevVertex Pharmaceuticals Incorpor
2017
Scott JamisonPerrigo Company plc
2011
Umang VohraDr Reddys Laboratories Ltd
2013
Sripada ChandrasekharDr Reddys Laboratories Ltd
2013
Michael PariniVertex Pharmaceuticals Incorpor
2017
John HendricksonPerrigo Company plc
2016
James MichaudPerrigo Company plc
2016
James DillardPerrigo Company plc
2019
Charles WagnerVertex Pharmaceuticals Incorpor
2019
John WesolowskiPerrigo Company plc
2016
Alok SonigDr Reddys Laboratories Ltd
2015
Thomas FarringtonPerrigo Company plc
2015
Cartikeya ReddyDr Reddys Laboratories Ltd
2016
Kimberly WhiteVertex Pharmaceuticals Incorpor
2018
Jeffrey NeedhamPerrigo Company plc
2009
Heidi ChenZoetis
2012
Glenn DavidZoetis
2016
Reshma KewalramaniVertex Pharmaceuticals Incorpor
2018
Marc CouckePerrigo Company plc
N/A
Michael StewartPerrigo Company plc
2004

Entity Summary

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York. Regeneron Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 7549 people.Regeneron Pharmaceuticals (REGN) is traded on BATS Exchange in USA and employs 7,549 people.

Regeneron Pharmaceuticals Leadership Team

Charles Baker, Independent Director
Joseph Goldstein, Independent Director
Anthony Coles, Independent Director
George Sing, Independent Director
Peter Powchik, Senior Vice President - Clinical Development
Jay Markowitz, Senior Vice President - Portfolio Management
Robert Terifay, Sr. VP of Commercial
Robert Landry, CFO and Sr. VP of Fin.
Michael Brown, Independent Director
Christine Poon, Independent Director
Neil Stahl, Executive VP of RandD
Marion McCourt, Senior Vice President and Head of Commercial
George Yancopoulos, Chief Scientific Officer and President - Regeneron Laboratories, Director
Huda Zoghbi, Director
Bonnie Bassler, Director
Joseph LaRosa, Senior Vice President General Counsel, Secretary
Daniel Plew, Senior Vice President General Manager - Industrial Operations and Product Supply
Leonard Schleifer, President CEO, Director
Alfred Gilman, Independent Director
Roy Vagelos, Chairman of the Board
Michael Aberman, Vice President - Strategy
Manisha Narasimhan, IR Contact
Douglas McCorkle, Vice President Controller, Assistant Treasurer
Marc TessierLavigne, Independent Director
Christopher Fenimore, Vice President Controller
Arthur Ryan, Independent Director

Stock Performance Indicators

Current Sentiment - REGN

Regeneron Pharmaceuticals Investor Sentiment

Majority of Macroaxis users are at this time bullish on Regeneron Pharmaceuticals. What is your perspective on investing in Regeneron Pharmaceuticals? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Currently Active Assets on Macroaxis

GOOG   
Purchased one share of
few hours ago
Traded for 1221.15
UGAZ   
Purchased over 100 shares of
few hours ago
Traded for 19.55
TWTR   
Purchased over 40 shares of
few hours ago
Traded for 43.23
JD   
Purchased over 60 shares of
few hours ago
Traded for 30.83
MDT   
Purchased few shares of
few hours ago
Traded for 111.18
Additionally take a look at Your Equity Center. Please also try Cryptocurrency Correlation module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins and exchanges.
Search macroaxis.com